HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer

Alberto Bretoni, Lucrezia Ferrario, Emanuela FogliaCentre for Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, ItalyPurpose: To investigate the implications of the introduction of two hormonal therapies, abiraterone acetate + predniso...

Full description

Bibliographic Details
Main Authors:	Bretoni A, Ferrario L, Foglia E
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-04-01
Series:	ClinicoEconomics and Outcomes Research
Subjects:	mCRPC multidimensional assessment economic evaluation multicriteria decision analysis hormonal therapies MCDA
Online Access:	https://www.dovepress.com/hta-and-innovative-treatments-evaluation-the-case-of-metastatic-castra-peer-reviewed-article-CEOR

Similar Items

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
by: Joshua P. Schiff, et al.
Published: (2019-05-01)

Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer
by: Gabrielle Robin, et al.
Published: (2024-08-01)

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
by: Mathieu Gaudreault, et al.
Published: (2023-03-01)

Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
by: Murali Kesavan, et al.
Published: (2021-03-01)

Immunotherapy in patients with metastatic castration-resistant prostate cancer: a meta-analysis of data from 7 phase III studies and 3 phase II studies
by: Anqiang Zhang, et al.
Published: (2022-09-01)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
by: Wout Devlies, et al.
Published: (2020-11-01)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
by: Matthew D. Tucker, et al.
Published: (2019-08-01)

Integrated high-throughput analysis identifies super enhancers in metastatic castration-resistant prostate cancer
by: Jie Zeng, et al.
Published: (2023-05-01)

Lower baseline testosterone level is related to earlier development of castration resistance in metastatic prostate cancer: a multi-center cohort study
by: Ho Ming Chris Wong, et al.
Published: (2024-02-01)

Revealing metastatic castration‐resistant prostate cancer master regulator through lncRNAs‐centered regulatory network
by: Rafaella Sousa Ferraz, et al.
Published: (2023-09-01)

Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview
by: Matteo Caracciolo, et al.
Published: (2024-10-01)

Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Tim Wollenweber, et al.
Published: (2021-09-01)

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2 Japanese Subgroup Analysis
by: Nobuaki Matsubara, et al.
Published: (2025-01-01)

Multi-protocol exploratory treatment for metastatic castration-resistant prostate cancer with BRCA mutations: a case report and literature review
by: Dongsheng Zhao, et al.
Published: (2023-05-01)

Current Routine Testosterone Immunoassays Are Unsuitable for Lowering the General Castration Cutoff Recommendation to <0.7 nmol/l (20 ng/dl)
by: Huub H. van Rossum, et al.
Published: (2023-02-01)

Impact of interdisciplinary tumor boards (ITB) and personalized treatment on survival outcomes in metastatic castration-resistant prostate cancer
by: Laura Lawaczeck, et al.
Published: (2025-03-01)

Assessment of Skeletal Tumor Load in Metastasized Castration-Resistant Prostate Cancer Patients: A Review of Available Methods and an Overview on Future Perspectives
by: Francesco Fiz, et al.
Published: (2018-07-01)

Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status
by: Zhengquan Xu, et al.
Published: (2021-03-01)

Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
by: Hualin Song, et al.
Published: (2020-03-01)

Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence
by: Jie Yang, et al.
Published: (2023-12-01)

Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials
by: Zhanyang Luo, et al.
Published: (2023-10-01)

Combination of C-reactive protein/albumin ratio and time to castration resistance enhances prediction of prognosis for patients with metastatic castration-resistant prostate cancer
by: Yozo Mitsui, et al.
Published: (2023-06-01)

Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review
by: Yuanzhuo Yan, et al.
Published: (2024-03-01)

Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study
by: Antti Rannikko, et al.
Published: (2025-01-01)

Recent advances in understanding DNA methylation of prostate cancer
by: Hyun Jin Shin, et al.
Published: (2023-05-01)

Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT
by: Florian Rosar, et al.
Published: (2024-05-01)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
by: Wei Ning, et al.
Published: (2023-09-01)

Prostate-speciﬁc antigen response after Abiraterone treatment in mCRPC: PSA as a predictor of overall survival
by: Alexandre Mendonça Macedo, et al.
Published: (2023-02-01)

Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
by: Majid Assadi, et al.
Published: (2022-12-01)

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with <sup>177</sup>Lu-PSMA and Combined <sup>225</sup>Ac- and <sup>177</sup>Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation
by: Thomas Langbein, et al.
Published: (2022-08-01)

Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy
by: Manuel Neuberger, et al.
Published: (2022-12-01)

<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
by: Kim N. Chi, et al.
Published: (2024-03-01)

Advances in <sup>177</sup>Lu-PSMA and <sup>225</sup>Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Sui Wai Ling, et al.
Published: (2022-10-01)

Real-world efficacy and safety of combined first-line treatment with PARP inhibitors and novel hormonal therapy in mCRPC patients with HRR gene mutations
by: Andong Guo, et al.
Published: (2024-12-01)

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
by: Tsukasa Yoshida, et al.
Published: (2022-09-01)

Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study
by: Ke Cheng, et al.
Published: (2022-07-01)

Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated with <sup>223</sup>RaCl<sub>2</sub>: Ten Years of Clinical Experience
by: Maria Silvia De Feo, et al.
Published: (2025-01-01)

Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET
by: David Ventura, et al.
Published: (2024-09-01)

Nomogram Analysis for Predicting Response to Androgen‐Receptor‐Axis‐Targeted Therapies in Patients With Metastatic Castration‐Resistant Prostate Cancer
by: I‐Hung Shao, et al.
Published: (2024-11-01)

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Friederike Völter, et al.
Published: (2021-03-01)